Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
| Author | |
|---|---|
| Abstract |
:
Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. The clinical relevance of the magnitude of the effect size is often debated. |
| Year of Publication |
:
2018
|
| Journal |
:
Alimentary pharmacology & therapeutics
|
| Date Published |
:
2018
|
| ISSN Number |
:
0269-2813
|
| URL |
:
http://dx.doi.org/10.1111/apt.14514
|
| DOI |
:
10.1111/apt.14514
|
| Short Title |
:
Aliment Pharmacol Ther
|
| Download citation |
